ipilimumab
Ultimovac's study in malignant melanoma is fully recruited
Despite challenges related to the pandemic, Norwegian biotechnology company Ultimovacs can now show progress in the clinical trial of malignant melanoma....
Strengthened clinical validation of Ultimovacs UV1 in the second quarter
For Norwegian Ultimovacs, the second quarter of the year was about...
Intervju
Immunicum updates clinical development strategy
Since Sven Rohmann took over as CEO of...
Ultimovacs takes up the fight against melanoma
Melanoma is the deadliest form of skin cancer and...
Ultimovac's path towards a universal cancer vaccine
Cancers represent a heavy burden on society and...